Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.21 USD | +0.98% | -3.99% | +64.40% |
05-13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
05-13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.40% | 2.63B | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- SVB Securities Adjusts Price Target on Merus to $48 From $35, Maintains Outperform Rating